Actinium Pharmaceuticals (NYSE:ATNM) vs. Xenetic Biosciences (NASDAQ:XBIO) Head to Head Contrast

Actinium Pharmaceuticals (NYSE:ATNM) and Xenetic Biosciences (NASDAQ:XBIO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Actinium Pharmaceuticals and Xenetic Biosciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actinium Pharmaceuticals	0	1	3	0	2.75
Xenetic Biosciences	0	1	0	0	2.00

Actinium Pharmaceuticals presently has a consensus target price of $4.00, suggesting a potential upside of 118.58%. Given Actinium Pharmaceuticals’ stronger consensus rating and higher probable upside, equities analysts clearly believe Actinium Pharmaceuticals is more favorable than Xenetic Biosciences.

Institutional & Insider Ownership

27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.1% of Xenetic Biosciences shares are owned by institutional investors. 6.0% of Actinium Pharmaceuticals shares are owned by company insiders. Comparatively, 14.7% of Xenetic Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Actinium Pharmaceuticals has a beta of -0.24, indicating that its share price is 124% less volatile than the S&P 500. Comparatively, Xenetic Biosciences has a beta of 2.31, indicating that its share price is 131% more volatile than the S&P 500.

Profitability

This table compares Actinium Pharmaceuticals and Xenetic Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%
Xenetic Biosciences	-161.63%	-49.51%	-43.99%

Earnings & Valuation

This table compares Actinium Pharmaceuticals and Xenetic Biosciences”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actinium Pharmaceuticals	$81,000.00	704.80	-$48.82 million	($1.39)	-1.32
Xenetic Biosciences	$2.50 million	1.87	-$4.14 million	($2.38)	-1.28

Xenetic Biosciences has higher revenue and earnings than Actinium Pharmaceuticals. Actinium Pharmaceuticals is trading at a lower price-to-earnings ratio than Xenetic Biosciences, indicating that it is currently the more affordable of the two stocks.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company’s research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

About Xenetic Biosciences

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.